Skip to main content
OpenTrials
Completed

NCT Number: NCT02901249

Cost- Effectiveness and Quality of Life Assessment in Major Depression Disorder

To evaluate the effectiveness of one algorithm for Major Depression Disorder (MDD) using medications available in the Brazilian Public Healthcare System (SUS), and assessment of the quality of life of these patients.

A randomized pragmatic trial was conducted. An algorithm was developed for the treatment of episodes of unipolar depression episodes.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

About this study

The study design was that of a pragmatic randomized clinical trial to evaluate the effectiveness of treatments for mood disorders in a public healthcare context in the city of Porto Alegre, in southern Brazil. The algorithm was originally developed for the treatment of major depression by a Delphi panel of experts from psychiatric associations in Brazil. All subjects provided an informed consent form, in writing, in order to participate in the study protocol, which was approved by the institutional ethics committee.

Procedures and measurements of the study

The subjects under evaluation were selected and they followed the stages defined by the treatment protocol:

  • Sample selection by being referred from the primary healthcare clinics in the municipality;
  • Informative talk about mood disorders and the research, with the informed consent forms being provided to the subjects;
  • Screening for unipolar depression episodes with the use of the Patient Health Questionnaire (PHQ-9), and Hypomanic Symptoms Checklist Brazilian Version (HCL -32-BV);
  • Diagnostic evaluation through the Mini International Neuropsychiatric Interview (MINI) and clinical interview for individuals with positive results in the screening instruments;
  • Baseline and demographic assessments using standardized semi-structured interviews in the first and second visits;
  • In each clinic visit, the severity of the symptoms were evealuated using the Clinical Global Impression Scale (CGI), Hamilton Rating Scale for Depression (HRSD), and Young Manic Rating Scale (YMRS);
  • Biweekly follow-up, changed to monthly after stabilization - with a maximum follow-up period of 52 weeks.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ages between 18 and 65;
  • current acute unipolar depression episode;
  • total capacity to understand and respond to self-applied instruments;
  • the presence of symptoms in the last 30 days;
  • abstinence for at least 30 days for drug addicts

Exclusion criteria

  • presence of Organic Brain Syndrome (OBS);
  • pregnancy or lactation;
  • criteria for psychiatric hospitalization.

Treatment and study plan

Sertraline

Drug

Other names: Cloridrate of sertraline

Nortriptyline

Drug

Other names: Cloridrate of nortrytyline

Lithium

Drug

Other names: Lithium Carbonate

Primary outcomes

  1. Number of Participants With Response to Treatment

    Time frame: 8 weeks

    Response to treatment was defined as a 50% reduction from baseline scores in Hamilton Rating Scale for Depression (HRSD). The HRSD is abbreviated version, consists of 17 items. The cutoff points are: 7-17 for mild depression,18-24 for moderate depression, and 25 or more for severe depression .

Secondary outcomes

  1. Number of Participants With Remission to Treatment

    Time frame: 8 months

    The remission outcome was established as obtaining three consecutive scores of values considered asymptomatic in the Hamilton Rating Scale for Depression (HRSD <7 points) . The subjects that were asymptomatic for at least 6-8 month were considered to be in remission, according to the criteria for partial and complete remission in the DSM-IV.

  2. Quality of Life -WHOQOL Intrument Scores

    Time frame: 12 weeks

    QOL scores as measured by World Heath Organization Quality of Life - WHOQOL -BREF instrument.

    scores 0-20 . Higher scores means a better outcome. The measure presented is a overall domain with the mean (SD)

Sponsors and collaborators

Lead sponsor

Federal University of Rio Grande do Sul

Other

Registry information

Official study title

Assessment of Cost- Effectiveness Interventions and the Quality of Life in Patients With Major Depression Through Resources Available in Brazilian Public Health

Important dates

Study start
2010
Primary completion
2014
Study completion
2015
First posted
Sep 15, 2016
Registry last updated
Oct 14, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.